Exacerbation Burden in COPD and Occurrence of Mortality in a Cohort of Italian Patients: Results of the Gulp Study
Pierachille Santus,Fabiano Di Marco,Fulvio Braido,Marco Contoli,Angelo Corsico,Claudio Micheletto,Girolamo Pelaia,Dejan Radovanovic,Paola Rogliani,Laura Saderi,Nicola Scichilone,Silvia Tanzi,Manlio Vella,Silvia Boarino,Giovanni Sotgiu,Paolo Solidoro
DOI: https://doi.org/10.2147/copd.s446636
2024-03-02
International Journal of COPD
Abstract:Pierachille Santus, 1 Fabiano Di Marco, 2 Fulvio Braido, 3 Marco Contoli, 4 Angelo Guido Corsico, 5 Claudio Micheletto, 6 Girolamo Pelaia, 7 Dejan Radovanovic, 1 Paola Rogliani, 8 Laura Saderi, 9 Nicola Scichilone, 10 Silvia Tanzi, 11 Manlio Vella, 11 Silvia Boarino, 11 Giovanni Sotgiu, 9 Paolo Solidoro 12 1 Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano, Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy; 2 Department of Health Sciences, Università degli Studi di Milano Pneumology, ASST Papa Giovanni XXIII, Bergamo, Italy; 3 Department of Internal Medicine (DiMI), Respiratory Unit for Continuity of Care, IRCCS Ospedale Policlinico San Martino, University of Genova, Genova, Italy; 4 Department of Translational Medicine, Respiratory Section, University of Ferrara, Ferrara, Italy; 5 Department of Medical Sciences and Infective Diseases, Unit of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation and University of Pavia Medical School, Pavia, Italy; 6 Cardio-Thoracic Department, Respiratory Unit, University Integrated Hospital, Verona, Italy; 7 Dipartimento di Scienze della Salute, Università Magna Graecia, Catanzaro, Italy; 8 Department of Experimental Medicine, Unit of Respiratory Medicine, University of Rome "Tor Vergata", Division of Respiratory Medicine, University Hospital "Tor Vergata", Rome, Italy; 9 Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy; 10 Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy; 11 AstraZeneca Italia, Milan, Italy; 12 Department of Medical Sciences, University of Turin, S.C. Pneumologia, Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Torino, Italy Correspondence: Pierachille Santus, Università degli Studi di Milano, Via G.B. Grassi 74, Milano, 20157, Italy, Tel +39 0239042801, Fax +39 0239042473, Email Objective: To describe the burden of moderate to severe exacerbations and all-cause mortality; the secondary objectives were to analyze treatment patterns and changes over follow-up. Design: Observational, multicenter, retrospective, cohort study with a three year follow-up period. Setting: Ten Italian academic secondary- and tertiary-care centers. Participants: Patients with a confirmed diagnosis of COPD referring to the outpatient clinics of the participating centers were retrospectively recruited. Primary and Secondary Outcome Measures: Annualized frequency of moderate and severe exacerbations stratified by exacerbation history prior to study enrollment. Patients were classified according to airflow obstruction, GOLD risk categories, and divided in 4 groups: A = no exacerbations; B = 1 moderate exacerbation; C = 1 severe exacerbation; D = ≥ 2 moderate and/or severe exacerbations. Overall all-cause mortality stratified by age, COPD category, and COPD therapy. A logistic regression model assessed the association of clinical characteristics with mortality. Results: 1111 patients were included (73% males), of which 41.5% had a history of exacerbations. As expected, the proportion of patients experiencing ≥ 1 exacerbation during follow-up increased according to pre-defined study risk categories (B: 79%, C: 84%, D: 97.4%). Overall, by the end of follow-up, 45.5% of patients without a history of exacerbation experienced an exacerbation (31% of which severe), and 13% died. Deceased patients were significantly older, more obstructed and hyperinflated, and more frequently active smokers compared with survivors. Severe exacerbations were more frequent in patients that died (23.5%, vs 10.2%; p-value: 0.002). Chronic heart failure and ischemic heart disease were the only comorbidities associated with a higher odds ratio (OR) for death (OR: 2.2, p-value: 0.001; and OR: 1.9, p-value: 0.007). Treatment patterns were similar in patients that died and survivors. Conclusion: Patients with a low exacerbation risk are exposed to a significant future risk of moderate/severe exacerbations. Real life data confirm the strong association between mortality and cardiovascular comorbidities in COPD. Keywords: pulmonary disease chronic obstructive, heart failure, ischaemic heart disease, respiratory medicine, public health Chronic obstructive pulmonary disease (COPD) is a treatable but debilitating medical condition associated with persistent symptoms and chronic airflow obstruction.<su -Abstract Truncated-
respiratory system